•
Sep 30, 2021
Bausch Health Q3 2021 Earnings Report
Bausch Health's third-quarter results demonstrated ongoing recovery from the COVID-19 pandemic, with key products growing and gaining market share, and strategic alternatives process progressing with planned IPOs for Solta Medical and Bausch + Lomb.
Key Takeaways
Bausch Health reported third-quarter 2021 revenues of $2.111 billion, GAAP net income of $188 million, and adjusted EBITDA of $885 million. The company is advancing its strategic alternatives process, expecting to launch the Solta Medical IPO in December 2021 or January 2022, followed by the Bausch + Lomb IPO approximately 30 days later.
Revenues reached $2.111 billion.
GAAP Net Income was $188 million.
Adjusted EBITDA (non-GAAP) amounted to $885 million.
GAAP Cash Generated from Operations totaled $564 million.
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Forward Guidance
Bausch Health reiterated guidance for the full year of 2021 with revenue range of $8.40 – $8.60 billion and Adjusted EBITDA (non-GAAP) range of $3.35 – $3.50 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income